Plasma Protease C1-inhibitor Treatment Market

Plasma Protease C1-inhibitor Treatment Market Size by Drug Class, Dosage Type, Distribution Channel, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2029

18.2%

CAGR (2023-2029)

3.88 USD Bn.

Market Size

319

Report Pages

165

Market Tables

Overview

Global Plasma Protease C1-inhibitor Treatment Market size was valued at USD 3.88 Bn in 2022 and is expected to reach USD 14.81 Bn by 2029, at a CAGR of 18.2 %.

Plasma Protease C1-inhibitor Treatment Market Overview

Plasma Protease C1-inhibitor (C1-INH) treatment, also known as C1-INH replacement therapy, is a medical intervention used to manage hereditary angioedema (HAE) and other conditions associated with C1-INH deficiency. By inhibiting enzymes involved in these systems, C1-INH reduces the excessive production of bradykinin, which is responsible for angioedema attacks. It is available in intravenous and subcutaneous formulations, and side effects are generally mild, including injection site reactions and rare hypersensitivity reactions. C1-INH replacement therapy is an effective intervention for managing HAE and can be used for both acute treatment and short-term prophylaxis. The increasing companies’ focus on the development of effective plasma protease C1 inhibitor treatment or drugs treating various health conditions including diabetic macular edema, HAE and others is expected to drive the influence of the market growth. lasma Protease C1-inhibitor Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Plasma Protease C1-inhibitor Treatment Market Drivers and Restrains:

The global plasma protease C1-inhibitor treatment market is expected to show robust growth in the forecast period due to the increasing cases of acute Hereditary Angioedema (HAE) and prophylaxis. The emergence of a few drug variants of C1-inhibitor is considered to be a major breakthrough for patients suffering from HAE. Berinert is a C1-esterase inhibitor for acute HAE that received approval from the European Union in 2011. Haegarda, which is derived from C1-esterase inhibitor is approved in the U.S for routine prophylaxis as a preventive measure against HAE attacks in adolescents and adults. The growing investment for innovation in inhibitor drugs, promising pipeline drugs and novel therapies, and increasing awareness for hereditary angioedema (HAE) are primarily driving the plasma protease C1-inhibitor market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Plasma Protease C1-inhibitor Treatment Market Segment Analysis:

Based on the drug class, the global plasma protease C1-inhibitor treatment market is segmented into C1-inhibitors, Kallikrein Inhibitor (Kalbitor) and Selective Bradykinin B2 Receptor Antagonist (Firazyr). The C1-inhibitors segment is accounted to the dominant share in the market in 2022. The wide usage of this drug class for the treatment of conditions such as prophylaxis and acute hereditary angioedema (HAE) is likely to keep their demand steady across the world. On the other hand, the Kallikrein inhibitor (Kalbitor) segment is expected to register a moderate CAGR of xx% during the forecast period owing to the rising preference for self-administrable drugs. Furthermore, the rising preference for Firazyr is projected to impede the growth of Kalbitor segment. The increasing approval of Kallikrein drugs and positive results obtained for pre-clinical treatment of HAE cases are likely to expand the growth rate of this segment moderately over the upcoming period. Plasma Protease C1-inhibitor Treatment Market

Based on the dosage type, the global plasma protease C1-inhibitor treatment market is segmented into lyophilized and liquid/injectable. The lyophilized segment held the largest market share in 2022 on the back of increasing practice of intravenous administration of drugs for the treatment of HAE. Additional, rising demand for intravenous C1 esterase inhibitor drugs in developing markets of Asia Pacific and Latin America is projected to positively impact the lyophilized segment. However, the liquid/injectable segment is expected to hold significant market share by 2029 due to the rising demand for subcutaneous administration of drugs, less adverse effects, cost effectiveness, and increased preference for Firazyr over Kalbitor by physicians.

Plasma Protease C1-inhibitor Treatment Market Regional Insights:

The global plasma protease C1-inhibitor treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America held the largest market share of the plasma protease C1-inhibitor treatment market in 2022. The regional market presents high demand for plasma protease C1-inhibitor treatment owing to the high prevalence of HAE in the U.S. Furthermore, Asia Pacific and Latin America are expected to hold the largest market share of plasma protease C1-inhibitor treatment market during the forecast period. Factors like increasing demand for advanced treatment options, developing economies, and increasing per capita income are anticipated to create growth avenues for the market players in emerging countries over the forecast period.

Plasma Protease C1-inhibitor Treatment Market Competitive landscape

Major Key players operating in this market are Shire plc, Pharming Group N.V., CSL Limited, and Sanquin. Manufacturers in the plasma protease C1-inhibitor treatment are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of global plasma protease C1-inhibitor treatment market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report.

External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global plasma protease C1-inhibitor treatment market dynamics, structure by analyzing the market segments, and project the global plasma protease C1-inhibitor treatment market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the global plasma protease C1-inhibitor treatment market make the report investor’s guide.

Plasma Protease C1-inhibitor Treatment Market Scope: Inquire before buying

Global Plasma Protease C1-inhibitor Treatment Market
Report Coverage	Details
Base Year:	2022	Forecast Period:	2023-2029
Historical Data:	2018 to 2021	Market Size in 2022:	US $ 3.88 Bn.
Forecast Period 2022 to 2029 CAGR:	18.2%	Market Size in 2029:	US $ 14.81 Bn.
Segments Covered:	by Drug Class	• C1-inhibitors • Kallikrein Inhibitor (Kalbitor) • Selective Bradykinin B2 Receptor Antagonist (Firazyr)
	by Dosage Type	• Liquid/Injectable • Lyophilized
	by Distribution Channel	• Hospital Pharmacies • Independent Pharmacies and Outlets

Plasma Protease C1-inhibitor Treatment Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Plasma Protease C1-inhibitor Treatment Market, Key Players:

• Shire plc
• Pharming Group N.V.
• CSL Limited
• Sanquin
• AbbVie
• Alexion
• Argenx
• Bluebird Bio
• Bristol-Myers Squibb/Celgene
• FibroGen
• Gilead
• GlaxoSmithKline
• Novartis
• Vertex
• Takeda Pharmaceutical Company Limited
• Ionis Pharmaceuticals, Inc.
• Pharming Technologies B.V.
• Centogene AG
• BioCryst Pharmaceuticals
• KalVista Pharmaceuticals, Inc
• CSL Behring LLC.
• Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
• Pharming Technologies B.V.
• KalVista Pharmaceuticals, Inc.
• BioCryst Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global Plasma Protease C1-inhibitor Treatment Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Plasma Protease C1-inhibitor Treatment Market?
Ans: The Global Plasma Protease C1-inhibitor Treatment Market is growing at a CAGR of 18.2% during forecasting period 2023-2029.

3. What is scope of the Global Plasma Protease C1-inhibitor Treatment market report?
Ans: Global Plasma Protease C1-inhibitor Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Plasma Protease C1-inhibitor Treatment market?
Ans: The important key players in the Global Plasma Protease C1-inhibitor Treatment Market are – Pharming Group N.V., CSL Limited, Sanquin, AbbVie, Alexion, Argenx, Bluebird Bio, Bristol-Myers Squibb/Celgene, FibroGen, Gilead, GlaxoSmithKline, Novartis, Vertex, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., and Centogene AG

5. What is the study period of this market?
Ans: The Global Plasma Protease C1-inhibitor Treatment Market is studied from 2022 to 2029.

Global Plasma Protease C1-inhibitor Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Plasma Protease C1-inhibitor Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast 6.1. Global Plasma Protease C1-inhibitor Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class 7.4. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Drug Class 7.6. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Drug Class 8. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast, by Dosage Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type 8.4. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Dosage Type 8.5. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Dosage Type 8.6. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Dosage Type 9. Global Plasma Protease C1-inhibitor Treatment Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel 9.4. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Distribution Channel 9.6. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Distribution Channel 10. Global Plasma Protease C1-inhibitor Treatment Market Analysis, by Region 10.1. Global Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Region 10.2. Global Plasma Protease C1-inhibitor Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Global Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis, by Region 11. North America Plasma Protease C1-inhibitor Treatment Market Analysis 11.1. Key Findings 11.2. North America Plasma Protease C1-inhibitor Treatment Market Overview 11.3. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class 11.4. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 11.4.1. C1-inhibitors 11.4.2. Kallikrein Inhibitor (Kalbitor) 11.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 11.5. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type 11.6. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 11.6.1. Liquid/Injectable 11.6.2. Lyophilized 11.7. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel 11.8. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Independent Pharmacies and Outlets 11.9. North America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country 11.10. North America Plasma Protease C1-inhibitor Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Plasma Protease C1-inhibitor Treatment Market Analysis, by Country 11.12. U.S. Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 11.12.1. C1-inhibitors 11.12.2. Kallikrein Inhibitor (Kalbitor) 11.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 11.13. U.S. Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 11.13.1. Liquid/Injectable 11.13.2. Lyophilized 11.14. U.S. Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Independent Pharmacies and Outlets 11.15. Canada Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 11.15.1. C1-inhibitors 11.15.2. Kallikrein Inhibitor (Kalbitor) 11.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 11.16. Steel Canada Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 11.16.1. Liquid/Injectable 11.16.2. Lyophilized 11.17. Canada Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Independent Pharmacies and Outlets 11.18. North America Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Dosage Type 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Plasma Protease C1-inhibitor Treatment Market Analysis 12.1. Key Findings 12.2. Europe Plasma Protease C1-inhibitor Treatment Market Overview 12.3. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class 12.4. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.4.1. C1-inhibitors 12.4.2. Kallikrein Inhibitor (Kalbitor) 12.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.5. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type 12.6. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.6.1. Liquid/Injectable 12.6.2. Lyophilized 12.7. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel 12.8. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Independent Pharmacies and Outlets 12.9. Europe Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country 12.10. Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Plasma Protease C1-inhibitor Treatment Market Analysis, by Country 12.12. Germany Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.12.1. C1-inhibitors 12.12.2. Kallikrein Inhibitor (Kalbitor) 12.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.13. Germany Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.13.1. Liquid/Injectable 12.13.2. Lyophilized 12.14. Germany Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Independent Pharmacies and Outlets 12.15. U.K. Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.15.1. C1-inhibitors 12.15.2. Kallikrein Inhibitor (Kalbitor) 12.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.16. U.K. Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.16.1. Liquid/Injectable 12.16.2. Lyophilized 12.17. U.K. Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Independent Pharmacies and Outlets 12.18. France Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.18.1. C1-inhibitors 12.18.2. Kallikrein Inhibitor (Kalbitor) 12.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.19. France Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.19.1. Liquid/Injectable 12.19.2. Lyophilized 12.20. France Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Independent Pharmacies and Outlets 12.21. Italy Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.21.1. C1-inhibitors 12.21.2. Kallikrein Inhibitor (Kalbitor) 12.21.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.22. Italy Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.22.1. Liquid/Injectable 12.22.2. Lyophilized 12.23. Italy Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Independent Pharmacies and Outlets 12.24. Spain Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.24.1. C1-inhibitors 12.24.2. Kallikrein Inhibitor (Kalbitor) 12.24.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.25. Spain Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.25.1. Liquid/Injectable 12.25.2. Lyophilized 12.26. Spain Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Independent Pharmacies and Outlets 12.27. Rest of Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 12.27.1. C1-inhibitors 12.27.2. Kallikrein Inhibitor (Kalbitor) 12.27.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 12.28. Rest of Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 12.28.1. Liquid/Injectable 12.28.2. Lyophilized 12.29. Rest Of Europe Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Independent Pharmacies and Outlets 12.30. Europe Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Dosage Type 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Overview 13.3. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class 13.4. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 13.4.1. C1-inhibitors 13.4.2. Kallikrein Inhibitor (Kalbitor) 13.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 13.5. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type 13.6. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 13.6.1. Liquid/Injectable 13.6.2. Lyophilized 13.7. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel 13.8. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Independent Pharmacies and Outlets 13.9. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Analysis, by Country 13.12. China Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 13.12.1. C1-inhibitors 13.12.2. Kallikrein Inhibitor (Kalbitor) 13.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 13.13. China Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 13.13.1. Liquid/Injectable 13.13.2. Lyophilized 13.14. China Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Independent Pharmacies and Outlets 13.15. India Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 13.15.1. C1-inhibitors 13.15.2. Kallikrein Inhibitor (Kalbitor) 13.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 13.16. India Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 13.16.1. Liquid/Injectable 13.16.2. Lyophilized 13.17. India Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Independent Pharmacies and Outlets 13.18. Japan Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 13.18.1. C1-inhibitors 13.18.2. Kallikrein Inhibitor (Kalbitor) 13.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 13.19. Japan Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 13.19.1. Liquid/Injectable 13.19.2. Lyophilized 13.20. Japan Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Independent Pharmacies and Outlets 13.21. ASEAN Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 13.21.1. C1-inhibitors 13.21.2. Kallikrein Inhibitor (Kalbitor) 13.21.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 13.22. ASEAN Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 13.22.1. Liquid/Injectable 13.22.2. Lyophilized 13.23. ASEAN Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Independent Pharmacies and Outlets 13.24. Rest of Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 13.24.1. C1-inhibitors 13.24.2. Kallikrein Inhibitor (Kalbitor) 13.24.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 13.25. Rest of Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 13.25.1. Liquid/Injectable 13.25.2. Lyophilized 13.26. Rest of Asia Pacific Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Independent Pharmacies and Outlets 13.27. Asia Pacific Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Dosage Type 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Overview 14.3. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class 14.4. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 14.4.1. C1-inhibitors 14.4.2. Kallikrein Inhibitor (Kalbitor) 14.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 14.5. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type 14.6. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 14.6.1. Liquid/Injectable 14.6.2. Lyophilized 14.7. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel 14.8. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Independent Pharmacies and Outlets 14.9. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Analysis, by Country 14.12. GCC Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 14.12.1. C1-inhibitors 14.12.2. Kallikrein Inhibitor (Kalbitor) 14.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 14.13. GCC Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 14.13.1. Liquid/Injectable 14.13.2. Lyophilized 14.14. GCC Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Independent Pharmacies and Outlets 14.15. South Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 14.15.1. C1-inhibitors 14.15.2. Kallikrein Inhibitor (Kalbitor) 14.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 14.16. South Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 14.16.1. Liquid/Injectable 14.16.2. Lyophilized 14.17. South Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Independent Pharmacies and Outlets 14.18. Rest of Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 14.18.1. C1-inhibitors 14.18.2. Kallikrein Inhibitor (Kalbitor) 14.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 14.19. Rest of Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 14.19.1. Liquid/Injectable 14.19.2. Lyophilized 14.20. Rest of Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Independent Pharmacies and Outlets 14.21. Middle East & Africa Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Dosage Type 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Plasma Protease C1-inhibitor Treatment Market Analysis 15.1. Key Findings 15.2. South America Plasma Protease C1-inhibitor Treatment Market Overview 15.3. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Drug Class 15.4. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 15.4.1. C1-inhibitors 15.4.2. Kallikrein Inhibitor (Kalbitor) 15.4.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 15.5. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Dosage Type 15.6. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 15.6.1. Liquid/Injectable 15.6.2. Lyophilized 15.7. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Distribution Channel 15.8. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Independent Pharmacies and Outlets 15.9. South America Plasma Protease C1-inhibitor Treatment Market Value Share Analysis, by Country 15.10. South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Plasma Protease C1-inhibitor Treatment Market Analysis, by Country 15.12. Brazil Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 15.12.1. C1-inhibitors 15.12.2. Kallikrein Inhibitor (Kalbitor) 15.12.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 15.13. Brazil Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 15.13.1. Liquid/Injectable 15.13.2. Lyophilized 15.14. Brazil Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Independent Pharmacies and Outlets 15.15. Mexico Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 15.15.1. C1-inhibitors 15.15.2. Kallikrein Inhibitor (Kalbitor) 15.15.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 15.16. Mexico Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 15.16.1. Liquid/Injectable 15.16.2. Lyophilized 15.17. Mexico Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Independent Pharmacies and Outlets 15.18. Rest of South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Drug Class 15.18.1. C1-inhibitors 15.18.2. Kallikrein Inhibitor (Kalbitor) 15.18.3. Selective Bradykinin B2 Receptor Antagonist (Firazyr) 15.19. Rest of South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Dosage Type 15.19.1. Liquid/Injectable 15.19.2. Lyophilized 15.20. Rest of South America Plasma Protease C1-inhibitor Treatment Market Forecast, by Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Independent Pharmacies and Outlets 15.21. South America Plasma Protease C1-inhibitor Treatment Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Dosage Type 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Shire plc 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Pharming Group N.V. 16.3.3. CSL Limited 16.3.4. Sanquin 16.3.5. AbbVie 16.3.6. Alexion 16.3.7. Argenx 16.3.8. Bluebird Bio 16.3.9. Bristol-Myers Squibb/Celgene 16.3.10. FibroGen 16.3.11. Gilead 16.3.12. GlaxoSmithKline 16.3.13. Novartis 16.3.14. Vertex 16.3.15. Takeda Pharmaceutical Company Limited 16.3.16. Ionis Pharmaceuticals, Inc. 16.3.17. Pharming Technologies B.V. 16.3.18. Centogene AG 16.3.19. BioCryst Pharmaceuticals 16.3.20. KalVista Pharmaceuticals, Inc 17. Primary Key Insights

Global Plasma Protease C1-inhibitor Treatment Market

Choose License Type